According to the Legislative Budget Board (LBB), SB 670 is not expected to have a significant fiscal impact on the state budget. The analysis assumes that any administrative costs related to implementing the bill could be absorbed within existing resources, meaning no additional funding or state appropriations would be required for execution.

Similarly, no fiscal impact is anticipated for local governments. The bill primarily affects patient access to investigational sun protection products and does not impose regulatory burdens or financial obligations on state or local agencies. Since the bill does not establish new state programs, funding structures, or reimbursement mechanisms, the financial implications are minimal.

The Texas Medical Board (TMB), which oversees medical practices in the state, is listed as the relevant agency for oversight. However, the bill does not require the TMB to take any significant enforcement actions, further minimizing any financial strain. In summary, SB 670 is expected to be fiscally neutral, with no significant cost to the state or local governments.

SB 670 aligns with principles of individual liberty, personal responsibility, and limited government. The bill allows patients to access investigational sun protection products that have completed phase one clinical trials but are not yet fully approved by the FDA. It emphasizes patient autonomy by ensuring individuals, in consultation with their physician, can make informed decisions about their healthcare without unnecessary government interference.

The legislation is modeled after the Texas Right to Try Act, which enables patients to use investigational treatments when conventional options are insufficient. By requiring informed consent and ensuring that physicians are not penalized for recommending investigational products, SB 670 safeguards both medical professionals and patients while maintaining ethical medical standards. Additionally, the bill protects manufacturers from liability and does not impose financial burdens on the state or local governments, as the Legislative Budget Board (LBB) confirmed.

From a policy perspective, the bill promotes free enterprise by allowing manufacturers to provide investigational products voluntarily while not mandating their availability. It also limits government intervention, preventing state officials from blocking patient access. Given its alignment with Texan values of healthcare freedom and minimal regulation, SB 670 represents a balanced approach to expanding patient choice while ensuring necessary safeguards. As such, Texas Policy Research recommends that lawmakers vote YES on SB 670.